Choosing Among the Psoriasis Biologics

What actually separates one psoriasis biologic from another?

Every biologic approved for plaque psoriasis is an antibody that intercepts one specific inflammatory signal, and that single fact explains most of what follows. The classes are named for what they block: tumor necrosis factor alpha, interleukin-17, interleukin-23, and the older interleukin-12/23 pathway. The AAD-NPF biologics guideline is organized the same way, class by class, because efficacy, monitoring, and cautions track the target rather than the brand name 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each..

A biologic is a protein drug grown in living cells that binds one messenger molecule in the immune system instead of dampening the whole system. That precision is why these drugs can clear skin that older systemic treatment could not, and why their cautions are narrower and more specific than the broad immune suppression that came before.

Biologics sit at the top of the psoriasis treatment ladder, above topical therapy and above phototherapy, which the AAD-NPF addresses as its own tier with its own indications, contraindications, and adverse effects 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.That phototherapy is a distinct treatment tier for psoriasis with its own indications, contraindications, and adverse effects, sitting below biologic therapy in the stepwise approach.. Arriving at this rung is not a failure of anything. It usually means the disease covers enough skin — or the wrong skin, the hands, the scalp, the genitals — that creams are not a realistic way to live.

What follows is a map of the three classes people are actually choosing between. It is deliberately not a ranking. The right class depends on facts about one person's joints, gut, heart, and insurance that no article can see.

TNF inhibitors: the class with the longest record

TNF inhibitors were the first biologics used in psoriasis and they remain the class with the deepest post-marketing history — adalimumab, etanercept, infliximab, certolizumab pegol. The AAD-NPF guideline recommends them for moderate-to-severe plaque psoriasis and sets out the screening and monitoring that comes with them 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each.. Two decades of observation is itself a form of information, and it is the argument for this class more often than any trial graph.

Two things keep TNF blockers in play. The first is familiarity: prescribers, pharmacists, and insurers all know these molecules, and biosimilar versions have made several of them markedly cheaper than the newer classes. The second is joints, which the section below takes up.

The cautions are specific, not vague. Screening for latent tuberculosis before the first dose is standard, because blocking TNF can let a dormant infection reactivate; hepatitis B screening follows the same logic. The guideline also flags caution in people with heart failure and in people with a history of demyelinating disease 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each..

On skin alone, this class generally does not clear as completely as the newer interleukin blockers. That trade-off is real, and it is why the conversation has moved. It is not a reason to refuse a TNF inhibitor. A drug that works, that is covered, and that treats your arthritis at the same time can be the better drug even when a comparison chart points elsewhere.

IL-17 inhibitors: fast, and deep on the skin

IL-17 inhibitors — secukinumab, ixekizumab, and brodalumab, which blocks the IL-17 receptor rather than the cytokine itself — are the class known for speed. Skin often begins to change within the first weeks of treatment, and the depth of clearance reported in trials is the high-water mark for psoriasis. The AAD-NPF guideline recommends this class for moderate-to-severe disease and details the monitoring particular to it 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each..

The class also carries cautions that genuinely change who gets it. IL-17 is part of how the body polices yeast at mucosal surfaces, so mild candida of the mouth, throat, or skin folds is the characteristic nuisance here. More consequentially, the guideline flags inflammatory bowel disease: IL-17 blockade can unmask or worsen Crohn disease and ulcerative colitis, which is why a personal or family history of IBD moves this class down the list 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each..

Where it tends to be chosen. Extensive disease where visible improvement soon matters — a wedding, a job that requires short sleeves, a person who has stopped leaving the house. Disease that has already failed a TNF inhibitor. And psoriasis with joint involvement, since the ACR/NPF psoriatic arthritis guideline includes IL-17 inhibitors among the options there 3Ref 3Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.The conditional recommendation to use a TNF-inhibitor biologic over an oral small-molecule drug as first-line treatment for active psoriatic arthritis, and the inclusion of IL-17 and IL-12/23 inhibitors among the alternative options..

If you have read about il-17 inhibitors and assumed the newer IL-23 class simply supersedes them, it does not. They are different tools with different tempos and different watch-outs.

IL-23 inhibitors: the newest class, and the fewest injections

IL-23 inhibitors — guselkumab, risankizumab, tildrakizumab — block the cytokine one step upstream of IL-17, and they are the newest group in wide use. Ustekinumab, which blocks the p40 subunit shared by IL-12 and IL-23, is the older cousin and is usually discussed alongside them. The AAD-NPF guideline covers all of these, including the spaced-out maintenance schedule that sets the class apart 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each..

Two features drive their popularity. Maintenance injections are spaced far apart — fewer needles across a year than either other class — and the side-effect profile has so far been the quietest, without the candida signal of IL-17 blockade or the tuberculosis and heart-failure cautions that shape TNF prescribing 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each.. For someone who dreads injections, that difference is not cosmetic; it is the difference between a treatment they stay on and one they quietly abandon.

The honest counterweight is time. This is the class with the shortest record, and a short record is not the same as a clean one — it is simply less observation. Newer does not automatically mean better for you. It means less is known, in both directions.

The il-23 inhibitors are frequently the first biologic offered to someone with skin-predominant psoriasis, no joint symptoms, and no pressing need for the fastest possible response.

Does psoriatic arthritis change which biologic you get?

Yes — it is the single fact most likely to override everything else on this page. When active psoriatic arthritis is present, the 2018 ACR/NPF guideline conditionally recommends starting a TNF-inhibitor biologic over an oral small-molecule drug as first-line treatment, with IL-17 and IL-12/23 inhibitors among the alternatives when a TNF inhibitor does not fit 3Ref 3Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.The conditional recommendation to use a TNF-inhibitor biologic over an oral small-molecule drug as first-line treatment for active psoriatic arthritis, and the inclusion of IL-17 and IL-12/23 inhibitors among the alternative options.. Joints are not a footnote to the skin disease; they redirect the whole decision.

The reason is asymmetry of damage. Skin recovers. Eroded cartilage and bone do not. So when both are inflamed, the drug is generally chosen for the joints and the skin is expected to follow.

How joint disease gets found. It is missed constantly, because people assume that stiff swollen fingers or a sore heel have nothing to do with a rash. The AAD-NPF comorbidities guideline recommends that clinicians actively screen people with psoriasis for psoriatic arthritis rather than wait for it to be volunteered 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That clinicians should screen for and stay aware of psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity in people with psoriasis rather than wait for these to be reported..

Morning stiffness that lasts more than an hour, a whole finger or toe swollen along its length, heel pain, or low-back pain that eases with movement rather than rest — these are worth naming out loud at a dermatology visit. They are the symptoms most likely to change the prescription, and they are the ones patients most often leave unmentioned because they seem like a different doctor's problem.

How the three classes line up side by side

None of the three classes is universally stronger; each is stronger for a different person. The table below summarizes the distinctions the AAD-NPF guideline draws, held at the level a patient can actually use — what the drug blocks, the practical rhythm of taking it, the caution that defines the class, and the situation where it tends to be the obvious pick 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each..

Read the last column as the common case, never as the rule. Plenty of people are correctly on the drug that column would not have predicted.

The table also leaves out most of what actually decides the prescription. What counts as moderate-to-severe, and how psoriasis severity is scored before a plan is approved, is settled earlier. And the full set of inputs behind choosing a psoriasis biologic — coverage and prior authorization, pregnancy plans, a prior cancer, how often someone is genuinely willing to inject — extends well past any grid.

What starting a biologic actually involves

Before the first dose there is a short workup: screening for latent tuberculosis, hepatitis serologies, and a review of vaccination status, since live vaccines are generally given before treatment starts rather than during it. The AAD-NPF guideline lays out this baseline and the ongoing monitoring appropriate to each class 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy for moderate-to-severe plaque psoriasis is organized by target class (TNF, IL-17, IL-23, IL-12/23), and the class-specific efficacy, dosing rhythm, cautions (latent tuberculosis and hepatitis B screening, heart failure and demyelinating disease for TNF; mucosal candida and inflammatory bowel disease for IL-17), and safety monitoring described for each.. For most people it is one blood draw and one conversation.

The injections. All three classes are given by injection under the skin, most of them with a prefilled pen used at home; infliximab is an infusion given in a clinic. Learning to inject is a short lesson from a nurse or pharmacist, not a skill.

Judging whether it worked. Response is assessed at a set follow-up visit, not week to week in a bathroom mirror. Photographs taken in the same light, on the same day of the week, are more honest than memory and make that visit far shorter.

Infection sense. The practical guidance most dermatologists give is to call rather than guess when a significant fever arrives, and to report a persistent cough or drenching night sweats promptly rather than waiting for the next scheduled appointment. That is not a reason to live carefully; it is one rule to hold, and it is nearly the whole of it.

Why the rest of your health belongs in this decision

Psoriasis is not only a skin disease, and the choice of biologic sits inside a larger picture. The AAD-NPF comorbidities guideline recommends awareness of and screening for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity in people with psoriasis 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That clinicians should screen for and stay aware of psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity in people with psoriasis rather than wait for these to be reported.. These are not incidental extras. They are part of what the condition is.

The cardiovascular association is the best characterized of them. A review in the Journal of the American College of Cardiology describes psoriasis as carrying increased cardiovascular risk driven by systemic inflammation, with the association stronger in more severe disease 5Ref 5Garshick MS, Ward NL, Krueger JG, Berger JS (2021).Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.The association between psoriasis and increased cardiovascular disease risk driven by systemic inflammation, with the association stronger in more severe disease. Used for the comorbidity association only, not for any individual risk estimate.. What that does and does not mean is worth stating plainly: it is a pattern across populations, not a forecast for any one person, and its practical consequence is ordinary — blood pressure, lipids, glucose, and tobacco get checked rather than deferred because the visit was about skin.

Depression and anxiety travel with visible skin disease often enough that the comorbidities guideline names them explicitly 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That clinicians should screen for and stay aware of psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity in people with psoriasis rather than wait for these to be reported.. A dermatology appointment is a legitimate place to say that the disease has changed how you dress, swim, date, or sleep. That is clinical information, not a complaint, and it can change which class gets chosen and how quickly.

None of this means psoriasis is dangerous in the way a frightening search result implies. It means the skin is one visible part of something systemic, and treating it well is part of treating the whole person.